Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upadacitinib + ABBV-722
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABBV-722 + upadacitinib is an investigational combination therapy being developed by AbbVie for the treatment of various inflammatory diseases. The combination consists of upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, and ABBV-722, a next-generation selective glucocorticoid receptor modulator (SGRM). Upadacitinib is an approved therapy (marketed as Rinvoq) that blocks the JAK-STAT signaling pathway, thereby reducing the production of pro-inflammatory cytokines. ABBV-722 is designed to activate the glucocorticoid receptor to induce anti-inflammatory effects while potentially minimizing the metabolic and systemic side effects typically associated with traditional high-dose corticosteroids. By targeting two distinct inflammatory pathways, the combination aims to provide enhanced clinical efficacy for immune-mediated conditions. It is currently being evaluated in Phase 1 clinical trials to assess safety and pharmacokinetic interactions.
- Other names
- upadacitinib
02
Targets
JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on upadacitinib + ABBV-722.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upadacitinib + ABBV-722.